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Nasopharyngeal carcinomas (NPC) are etiologically related to the Epstein-Barr virus (EBV), and malignant
NPC cells have consistent although heterogeneous expression of the EBV latent membrane protein 1 (LMP1).
LMP1 trafficking and signaling require its incorporation into membrane rafts. Conversely, raft environment
is likely to modulate LMP1 activity. In order to investigate NPC-specific raft partners of LMP1, rafts derived
from the C15 NPC xenograft were submitted to preparative immunoprecipitation of LMP1 combined with mass
spectrometry analysis of coimmunoprecipitated proteins. Through this procedure, galectin 9, a beta-galacto-
side binding lectin and Hodgkin tumor antigen, was identified as a novel LMP1 partner. LMP1 interaction with
galectin 9 was confirmed by coimmunoprecipitation and Western blotting in whole-cell extracts of NPC and
EBV-transformed B cells (lymphoblastoid cell lines [LCLs]). Using mutant proteins expressed in HeLa cells,
LMP1 was shown to bind galectin 9 in a TRAF3-independent manner. Galectin 9 is abundant in NPC biopsies
as well as in LCLs, whereas it is absent in Burkitt lymphoma cells. In subsequent experiments, NPC cells were
treated with Simvastatin, a drug reported to dissociate LMP1 from membrane rafts in EBV-transformed B
cells. We found no significant effects of Simvastatin on the distribution of LMP1 and galectin 9 in NPC cell
rafts. However, Simvastatin was highly cytotoxic for NPC cells, regardless of the presence or absence of LMP1.
This suggests that Simvastatin is a potentially useful agent for the treatment of NPCs although it has distinct
mechanisms of action in NPC and LCL cells.
Nasopharyngeal carcinoma (NPC) is one of the best exam-
ples of a human solid tumor which is consistently associated
with a virus (7). NPC is rare in Europe and North America (3
cases/100,000 persons/year), but it remains a major public
health problem in several areas of Asia and Africa. Very-high-
incidence foci are found in south China, especially in Guan-
dong and Guangxi provinces (25 to 40 cases per 100,000 per-
sons per year) and also in other populations of southeast Asia,
for example, in the Sarawak people of Borneo island (14).
Intermediate risk areas include the Philippines, Vietnam,
Indonesia, and several countries of North and West Africa
(incidence of 4 to 8 cases/100,000 persons/year). Most NPCs
have minimal epithelial maturation and are classified as undif-
ferentiated (World Health Organization [WHO] type III) or
poorly differentiated (WHO type II). A few cases are differ-
entiated (WHO type I). Epstein-Barr virus (EBV) association
is constant regardless of patient origin and tumor differentia-
tion except for some very rare cases of differentiated NPC
(type I) in western countries (47). Another striking constant
feature of NPC is the presence of a massive lymphoid infiltrate
in the primary tumor. This infiltrate contains mostly T lympho-
cytes and a minority of B cells, monocytes, eosinophils, and
dendritic cells. It results at least in part from a massive pro-
duction of inflammatory cytokines by malignant cells, including
interleukin 1, interleukin 1 and macrophage inhibitory pro-
tein 1 (6, 26, 57).
EBV infection in NPC cells is mainly latent. Several copies
of the EBV genome (about 170 kb) are contained in the nuclei
of malignant cells, generally in the form of circular indepen-
dent DNA molecules called episomes. Most of the about 80
EBV genes are silent in NPC cells, but some of them are
consistently expressed (50). Two of these genes encode small
untranslated EBV-encoded RNAs (28). Other EBV genes con-
sistently transcribed in NPC encode viral proteins with proven
or suspected oncogenic properties like Epstein-Barr nuclear
antigen 1 (EBNA1), latent membrane protein 1 (LMP1) and
LMP2, and the BARF1 protein (5, 23, 55). Currently, only
EBNA1 and LMP1 are detected in NPC cells by routine
immunohistochemistry (detection of LMP2 requires special
techniques to enhance antibody staining) (23). EBNA1 is a
chromatin-associated protein that is involved in EBV genome
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maintenance and is also suspected to have an oncogenic role
(34). LMP1, which is regarded as the main EBV oncoprotein,
is a membrane-associated protein trafficking in the internal
and plasma membranes. Its role in NPC oncogenesis has been
questioned because its expression is heterogenous, variable
from one biopsy to another and within a given specimen (16)
(36). However, extensive sequence analysis of EBV tumor iso-
lates reveals frequent invalidation of LMP1 T-cell epitopes and
strongly suggests that it is expressed in NPC cells despite a
negative pressure of the immune system (17). This observation
supports the notion that LMP1 has a role in the malignant
phenotype of NPC cells. In addition, we have found that LMP1
expression is more consistent and abundant in the juvenile
form of North African NPCs, which differs from the adult form
by several clinical and biological characteristics (35, 36).
LMP1 is a 386-amino-acid protein with a short N-terminal
intracytoplasmic domain (24 residues), six transmembrane seg-
ments joined by short internal and external loops, and a long
C-terminal intracytoplasmic domain (190 residues). The N-
terminal domain and the transmembrane segments have a key
role in membrane anchoring, intracellular trafficking, and self-
aggregation of the protein (19, 29, 65). On the other hand, the
C-terminal intracytoplasmic domain can bind a series of cellu-
lar signaling adaptors including TRAF3, tumor necrosis factor
receptor-associated death domain (TRADD) protein, and the
gp85 subunit of the phosphatidylinositol 3-kinase (46), (37),
(13). There is a suspicion that the N terminus and transmem-
brane portions can also bind signaling adaptors, but so far none
has been formally identified (33, 49, 65). LMP1 has the ability
to activate a wide range of signaling pathways. The assortment
of these pathways and the resulting effects are dependent on
the context of the host cell, the nature of LMP1 strain poly-
morphisms, and LMP1 cellular concentration (18, 27, 39, 45,
66). In EBV-transformed B cells, LMP1 signaling pathways are
adjusted in order to draw cells through the G1/S checkpoint
and simultaneously prevent apoptosis in a majority of cells
(15). There is a consensus that three types of molecular pro-
cesses are required for optimal activation of most LMP1 sig-
naling pathways: its own oligomerization; the capture of its
signaling adaptors, especially TRAF3, TRAF6, and TRADD;
and its incorporation into membrane rafts (19, 32, 43, 64).
Membrane rafts are microdomains of the cell membrane net-
work characterized by a high content in cholesterol and glyco-
sphingolipids. These microdomains are sites of preferential
attachment for glycosylphosphatidylinisitol-anchored (external
membrane layer) and nonreceptor tyrosine kinases (internal
membrane layer). Most raft components are recovered as
buoyant complexes through a procedure of cell fractionation
and flotation on a density gradient. Most authors simply iden-
tify membrane rafts to buoyant complexes, as we will do our-
selves in the rest of this report. However, one needs to keep in
mind that there are several categories of rafts that are not
discriminated by flotation assays although they have distinct
content in situ (48). The exact nature of the raft-like complexes
carrying LMP1 has remained elusive since we first reported the
association of LMP1 with these subcellular elements (11). Al-
though we along with others have shown that LMP1 recruits its
main signaling adaptor TRAF3 in raft-like complexes, so far
we have not been able to identify additional cellular partners of
LMP1 in these structures (1, 2, 24, 32, 65). Kaykas et al. (32)
have reported that artificial targeting of the LMP1 C-terminal
domain to classical membrane rafts only partially restores its
signaling activity. As noted by these authors, there is something
“special” in natural rafts carrying LMP1 that is required for its
maximal signaling ability.
In order to progress in the characterization of these com-
plexes, we undertake to identify novel partner proteins associ-
ated with LMP1 in membrane rafts using a direct approach
based on preparative immunoprecipitation and mass spec-
trometry (MS) analysis. This approach was applied to NPC
cells having spontaneous LMP1 expression. We report that
LMP1 interacts with galectin 9, a protein previously identified
in Hodgkin’s disease, which appears to be extremely abundant
in NPC cells. Association of LMP1 and galectin 9 with the rafts
was not inhibited by the raft-modifying agent Simvastatin, in
contrast with a previous report regarding EBV-transformed B
cells (31). However, Simvastatin appeared to be highly cyto-
toxic for NPC cells by an LMP1-independent mechanism.
MATERIALS AND METHODS
Tumor and cell lines. C15 and C17 are EBV-positive NPC tumor lines per-
manently propagated by subcutaneous passage into nude mice (6). C666-1 is an
EBV-positive NPC cell line which can be propagated by in vitro culture (9). It
was kindly provided by D. P. Huang and K. W. Lo (Chinese University of Hong
Kong). C15 cells consistently produces LMP1, whereas LMP1 production is
undetectable at the protein level in C17 and C666-1 cells (9, 11). Non-NPC
malignant epithelial cell lines were also used: HeLa (cervix carcinoma), A431
(vulvar epidermoid carcinoma), and HT 29 and HCT 116 (both colonic carci-
nomas). EBV1 and NADC15 are lymphoblastoid cell lines (LCL) resulting
from EBV transformation of normal B lymphocytes and are infected with the
B95-8 and the C15 strain of EBV, respectively (1). Several Burkitt lymphoma cell
lines were used: Ramos (EBV negative), BL2 (EBV negative), and Daudi (EBV
positive without endogenous LMP1 expression). BL2-B95 resulted from the
conversion of BL2 by the B95-8 strain of EBV. Daudi-LMP6 is a subclone of
Daudi transfected with the B95-8 LMP1 gene under the control of the human
metallothionein promoter (63).
Eukaryotic expression vectors and transfections. All transfected genes were
expressed by short-term transfections, except for the previously described HL8
clone derived from HeLa cells and having stable expression of the full-length
B95-8 LMP1 under the control of the metallothionein promoter (2). Short-term
transfections were also done in HeLa cells using DOTAP (N-[1-(2,3-diole-
oyloxy)propyl]-N,N,N-trimethylammonium methylsulfate) cationic liposomes
(Roche Molecular, Meylan, France). Cells were harvested 24 h after transfection.
The full-length galectin 9 cDNA encoding the shortest isoform lacking exons 5
and 10 was expressed under the control of the cytomegalovirus (CMV) promoter
in the pBK-CMV plasmid from Stratagene (La Jolla, CA). LMP1 cDNA from
the B95-8 strain, either full-length or deleted of the PXQXT motif at codons 204
to 208, was expressed from the pcDNA3 plasmid (Invitrogen) (2).
Antibodies. LMP1 was detected using three types of reagents. CS1-4 (Dako-
Cytomation, Denmark) is a pool of four monoclonal antibodies directed to the
C terminus of LMP1; its target epitopes map in the variable 11 amino acid
repeats between residues 205 to 308 and close to residue 386 at the very
C terminus (44, 52). CS1-4 was used under the form of hybridoma culture
supernatant, as provided by the manufacturer. OT21C is a monoclonal antibody
that reacts with a conformational epitope mapping at residues 290 to 318, thus
overlapping the 11 amino acid repeats of LMP1 (44). OT21C was affinity purified
and used mainly for immunoprecipitation. OT22CN is a monoclonal antibody
that reacts with an epitope contained in residues 1 to 23 in the amino-terminal
intracytoplasmic portion of LMP1 (44). It was also affinity purified prior to its use
in this study. Galectin 9 was detected using an affinity-purified polyclonal anti-
body raised against the C-terminal carbohydrate recognition domain of human
galectin 9, whose central motif maps at residues 287 to 293. Affinity-purified
antibodies against TRAF3 (H122), Lyn (clone 42), poly(ADP-ribose) polymer-
ase (PARP; clone C-2-10) and CD40 (monoclonal antibody [MAb] 89) were
from Santa Cruz (Heidelberg, Germany), Transduction Laboratories (Becton
Dickinson, Le Pont de Claix, France), Merck Biosciences (Darmstadt,
Germany), and Beckman Coulter (Villepinte, France), respectively. The anti-
CD40 antibody G28-5 was produced using the corresponding hybridoma
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(American Type Culture Collection; clone HB 9110) and purified by protein A
chromatography.
Whole-tumor or cultured cell protein extraction. Small tumor pieces were
transferred in a small volume of RIPA buffer (150 mM NaCl, 25 mM Tris-HCl,
pH 7.5, 5 mM EDTA, 0.5% sodium deoxycholate, 0.5% NP 40, 0.1% sodium
dodecyl sulfate [SDS]) supplemented with Complete protease inhibition mix-
ture according to the manufacturer’s instructions (Roche Molecular, Meylan,
France). Tumor pieces were homogenized in a tight-fitting conical glass homog-
enizer and sonicated (three times for 10 s each time) on ice. Extracts were
clarified by centrifugation for 15 min at 16,000  g at 4°C. Cultured cells were
simply solubilized in RIPA buffer with Complete protease inhibition mixture,
sonicated, and clarified in the same way as for tumor extracts.
Isolation of rafts (flotation assay). Rafts were isolated by Triton X-100 ex-
traction and flotation through a sucrose step gradient as previously described
(1, 2, 11). Briefly, tumor pieces (500 mg) or cell suspensions (about 108 cells)
were homogenized at 4°C in 3 ml of MES (morpholineethanesulfonic acid)-
buffered saline (MBS) containing 1% Triton X-100 and the protease inhibition
mixture (Complete). A 100-l aliquot of this unfractionated extract was saved for
Western blot analysis (designated initial extract). The remainder was clarified by
centrifugation at 50  g for 2 min. The pellet was collected and named LSP (low
speed pellet). The clarified homogenate was made up to 4 ml in 1.2 M (40%)
sucrose–MBS–Triton at 4°C, transferred to an SW41 ultracentrifuge tube, and
overlaid with 4.5 ml of 0.9 M (30%) sucrose-MBS buffer (without Triton) and a
third layer of 2.7 ml of MBS (without sucrose). This step gradient was centri-
fuged at 180,000 g at 4°C in an SW41 Ti Beckman rotor for 18 to 20 h. The raft
fraction, visible as an opaque band 5 mm below the interface of the upper and
middle gradient layers, was harvested. The sample was diluted to a final volume
of 3 ml in MBS and pelleted in a TLA 100.3 Beckman rotor (300,000  g at 4°C
for 60 min). The amount of proteins in the upper and the 30% sucrose layers
were consistently negligible. The 40% sucrose layer was collected and named
fraction F40. Finally, a pellet of heavy Triton-insoluble material was retained and
named fraction HSP (high speed pellet). For protein assays and Western blot
analysis, the LSP, HSP, and raft pellets were solubilized in approximately 10
volumes of RIPA buffer supplemented with SDS (6% final concentration). Sim-
ilarly, aliquots of the unfractionated lysate and the F40 fractions were further
diluted and homogenized in 6% SDS-RIPA buffer. Rafts were used for prepar-
ative or analytical immunoprecipitations. In other experiments, all fractions—
initial extract, LSP, HSP, rafts, and F40—were analyzed by direct polyacrylamide
gel electrophoresis (PAGE) and Western blotting. The relative concentration of
various protein species in the rafts by comparison with the initial extract was
estimated by the ratio of the densitometric “volumes” (V) of the corresponding
bands: V raft/V initial.
Protein concentration assay. In all tumor and cell extracts or fractions, protein
concentration was assayed by the Lowry method using a detergent-compatible
microassay system (Bio-Rad, Marnes-la-Coquette, France).
Western blotting. Western blotting was performed on polyvinylidene difluo-
ride membranes (Immobilon P; Millipore, St. Quentin en Yvelines, France)
according to standard protocols, using horseradish peroxidase-conjugated sec-
ondary antibodies and the ECL system (Amersham, Les Ulis, France). In one
instance (see Fig. 2c), a Supersignal Westfemto kit (Pierce, Brebie`res, France)
was used for revelation of horseradish peroxidase-conjugated secondary antibod-
ies instead of the ECL system. For a given PAGE gel, the amounts of total
proteins loaded in each lane were identical (for example, 30 g). When required,
densitometry of the chemiluminescence films was done using a GS-710 cali-
brated imaging densitometer with Quantity One software (Bio-Rad, Marnes-
la-Coquette, France).
Immunoprecipitations. Affinity-purified antibodies were loaded on magnetic
beads according to the manufacturer’s instructions (Dynal Biotech ASA, Com-
pie`gne, France). Pan-mouse immunoglobulin G (IgG) or protein A Dynabeads
were used for murine monoclonal or rabbit polyclonal antibodies, respectively.
For some experiments, antibodies were covalently cross-linked on magnetic
beads using DMP (dimethyl pimelimidate dihydrochloride) according to the
manufacturer’s instructions (Dynal Biotech).
(i) Preparative immunoprecipitations. Preparative immunoprecipitations
were made on raft complexes prior to tandem MS (MS/MS) analysis, using 45 g
of OT21C monoclonal antibody covalently cross-linked on 4.5  108 pan-mouse
IgG Dynabeads. Purified mouse IgG1 was used for some of the negative controls
(Sigma). Antigen capture was performed by overnight incubation of 4.5  108
IgG-loaded beads with a raft sample corresponding to 180 g of protein diluted
in 1.8 ml of immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1% Triton X-100). Magnetic beads carrying the immune complexes were sub-
sequently washed six times in washing buffer (10 mM Tris-HCl, pH 7.4, NaCl
150 mM, 1% Triton X-100, 60 mM octyl -D-glucopyranoside). Precipitated
proteins were eluted by boiling the beads for 5 min in 120 l of a modified form
of Laemmli buffer with a high content of SDS (50 mM Tris, 75 mM NaCl, 2.5 mM
EDTA, 10% glycerol, 5% SDS). A small aliquot of eluted proteins (6 l) was
saved for quality controls of the immunoprecipitation step based on Western blot
detection of LMP1 and TRAF3. The rest was further processed for MS analysis.
(ii) Analytical immunoprecipitations. Analytical immunoprecipitations were
done using the same basic procedure, with some modifications according to the
type of precipitating antibodies and the type of tumor or cell extract. Analytical
immunoprecipitations were made on the rafts with anti-LMP1 monoclonal an-
tibodies using the above-mentioned conditions, except that only 5 g of anti-
bodies was loaded on 5  107 beads in order to save reagents (without covalent
cross-linking unless otherwise mentioned). Loaded beads were then incubated
with a raft sample containing 60 g of protein diluted in 600 l of immunopre-
cipitation buffer (unless otherwise mentioned). Eluted proteins were analyzed by
Western blotting. The same procedure was carried out for immunoprecipitation
on whole-tumor extracts except for two points: loaded beads were incubated with
a sample of tumor extract containing 120 g of protein in 600 l of immuno-
precipitation buffer, and protease inhibition mixture (Complete) was added to
the immunoprecipitation buffer. For direct immunoprecipitation of galectin 9, an
affinity-purified polyclonal antibody was bound to protein A Dynabeads at a ratio
of 10 g to 80 l of beads. Rabbit nonspecific purified immunoglobulins were
used for the control experiments (Sigma). Antigen capture was performed by a
4-h incubation of 20 l of Ig-loaded beads with a raft sample corresponding to
30 g of protein or 30 l of loaded beads with 120 g of whole-cell extract.
MS analysis of proteins coimmunoprecipitated with LMP1. (i) SDS-PAGE
separation and protein digestion. Precipitated proteins eluted from beads were
loaded in a 5% SDS-PAGE gel for a short migration (about 1 cm) in order to
remove detergents incompatible with MS analysis and further reduce the com-
plexity of the eluted samples. Unstained segments of gel lanes containing pro-
teins were cut in nine slices (width, about 1 mm) from low to high molecular
weights. Each slice was treated as a distinct source of protein digests. Practically,
slices were cut in 1- by 1-mm pieces which were washed three times by sequential
immersions in 25 mM NH4 · HCO3 and plain acetonitrile and then dried. Dried
gel pieces were reduced and alkylated by using dithiothreitol and iodoacetamid,
respectively. Gel pieces were dried again after a new cycle of washes as described
above. In-gel trypsin digestion was performed overnight at 30°C (20 ng/l in NH4 ·
HCO3 solution; Sigma). Finally, protein digests were extracted by the addition to
gel pieces of a mixture of acetonitrile–H2O–HCOOH (60:35:5 [vol/vol/vol]),
followed by sonication and centrifugation. Supernatants containing tryptic pep-
tides were vacuum dried to a very small volume (1 or 2 l) and then diluted again
in 5% acetonitrile (H2O, 95%).
(ii) Liquid chromatography andMS/MS analysis. Concentrated peptides were
separated on an LC Packings system (Dionex) coupled to the nanoelectrospray
II ionization interface of a QSTAR/Pulsar I (Applied Biosystems). The MS/MS
data from the different experiments were analyzed using MASCOT software on
an internal server (Matrix Science, London, United Kingdom). The protein
search was done in three rounds, one without taxonomic restrictions, one against
the NCBI human database, and one against the murine database.
Confocal immunofluorescence analysis. Cells were fixed on poly-L-lysine slides
at room temperature using 4% paraformaldehyde for 15 min, permeabilized in
0.1% SDS in phosphate-buffered saline (PBS) for 10 min, and then incubated for
20 min with 10% FCS–0.2% bovine serum albumin–PBS for saturation of non-
specific binding sites. Antibodies were diluted in PBS–0.2% bovine serum albu-
min. The mouse monoclonal OT22CN directed to the N-terminal domain of
LMP1 was diluted to 2 g/ml. The rabbit polyclonal antibody against galectin 9
was the same as for Western blotting, used at 5 g/ml. Secondary anti-mouse and
anti-rabbit antibodies were conjugated to Alexa 546 and Alexa 488, respectively
(Molecular Probes, Invitrogen, Cergy-Pontoise, France). Observations were
made with a confocal microscope (Zeiss LSM510).
Immunostaining of fresh NPC biopsies. Tissue sections were dewaxed, rehy-
drated, and microwaved at 98°C for 20 min in citrate buffer (10 mM, pH 7.3).
After endogenous peroxidase was blocked with H2O2, they were incubated with
the affinity-purified anti-galectin 9 rabbit antibody at 5 g/ml for 60 min at room
temperature. In the next step, sections were incubated with the EnVision poly-
mer (DakoCytomation, Trappes, France) conjugated to peroxidase for 45 min at
room temperature and subsequently with diaminobenzidine used as a chromo-
genic substrate of peroxidase. Finally, sections were counterstained with Mayer’s
hematoxylin for 8 s, dehydrated, and mounted.
Electron microscopy. Cell pellets were fixed with 1.6% glutaraldehyde at 4°C,
followed by treatment with osmium tetroxide, and then dehydrated and embed-
ded in Epon resin. Ultrathin sections were cut on an LKB-III ultra-microtome,
stained for contrast with uranyl acetate and lead citrate, and examined with a
Zeiss EM 902 transmission electron microscope.
13328 PIOCHE-DURIEU ET AL. J. VIROL.
In vitro pharmacological assays on NPC cells. Prior to in vitro experiments,
xenografted C15 tumors were minced and treated with type II collagenase for
cell dispersion as previously described (54). Residual cell aggregates were re-
moved by filtration on a nylon cell strainer with 100-m pores. C15 cell suspen-
sions were grown in HEPES-buffered RPMI medium with 7.5% fetal calf serum
on plastic coated with poly(2-hydroxyethylmethacrylate) (polyHEMA; Sigma,
Saint-Quentin Fallavier, France), an antiadhesive polymer that inhibits cell at-
tachment (60). Using this coating procedure, proliferation of murine fibroblasts
was completely inhibited, whereas NPC cells grew as nonanchored spheroids or
aggregates about 150 m in diameter. Preactivated Simvastatin was solubilized in
dimethylsulfoxide (DMSO; 10 mM stock solution) (Calbiochem/Merck). For
biochemical experiments, C15 cells were seeded in 24-well plates at 1 million
cells/well in 1.5 ml of culture medium and incubated with Simvastatin for 5 days
at a final concentration of 5 M. Control cells were incubated in culture medium
with 0.05% DMS0. To provide a control for PARP cleavage, C15 cells were
treated for 12 h with the CD95 agonist antibody 7C11 (250 ng/ml) (Becton-
Dickinson Biosciences, Le Pont de Claix, France). For toxicity assays, NPC cells
were seeded in 96-well plastic microplates coated with polyHEMA at 75  103
cells/well in 150 l of culture medium. Cell viability was evaluated using the
WST-1 assay based on a soluble form of MTT [3-(4,5-dimethylthiazol-2-yl)2
2,5-diphenyl tetrazolium bromide] according to the manufacturer’s instructions
(Roche Molecular, Meylan, France). Cells were incubated with 10 l of the
WST-1 reagent added to the culture medium for 4 h at 37°C. The plates were
subsequently read on an enzyme-linked immunosorbent assay reader (Dynatech
MR7000) using a 450-nm filter. The mean and standard deviation were deter-
mined for quadruplicate samples.
RESULTS
Determination of optimal conditions for preparative immu-
noprecipitations of LMP1. We intended to identify novel pro-
teins associated with LMP1 into lipid rafts derived from NPC
cells including indirect partners and proteins whose expression
was restricted to the NPC cell lineage. We chose a strategy
based on preparative immunoprecipitation of LMP1-carrying
complexes. Total raft complexes were isolated from C15 NPC
tumor tissue by extraction in Triton lysis buffer and flotation on
a density gradient. In the next step, LMP1-carrying complexes
FIG. 1. Assessment of preparative LMP1 immunoprecipitation
from C15 rafts using the OT21C antibody. Samples of C15 rafts cor-
responding to 60 g of protein were submitted to immunoprecipitation
using 15 g of purified OT21C or irrelevant mouse IgG1 covalently
bound to 1.5  108 magnetic beads. Parallel blots were stained with
anti-LMP1 (CS1-4), anti-TRAF3, and anti-Lyn. The last blot was
restained with -actin antibodies. Input, raft-derived proteins saved
prior to the immunoprecipitation step (5 g, LMP1; 10 g, TRAF3,
Lyn, and -actin); mIgG1, one-third of the eluted proteins recovered
from control immunoprecipitation (irrelevant mouse IgG1); OT21C,
one-third of the eluted proteins recovered from LMP1 immunopre-
cipitation. Using the above-mentioned ratios of magnetic beads, anti-
bodies, and raft proteins, about 100% of LMP1 and 50% of TRAF3
were recovered by immunoprecipitation with OT21C. All the experi-
ments depicted in this and subsequent figures were performed at least
twice.
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were captured using anti-LMP1 antibodies adsorbed on mag-
netic beads. This procedure was performed in experimental
conditions compatible with preservation of raft lipid-protein
interactions (1% Triton at 4°C in the absence of ionic deter-
gents). During preliminary experiments OT21C was selected as
the best precipitating antibody, being more efficient than S12
or OT22CN (data not shown). OT21C has been shown to bind
a conformational epitope in the C-terminal intracytoplasmic
region of LMP1 within residues 290 to 318 (44). Optimal ratios
of antibody, magnetic beads, raft material, and reaction buffer
volumes were determined in subsequent experiments. We
found that it was possible to immunoprecipitate 100% LMP1
from a sample of C15 rafts corresponding to 60 g of proteins,
using 1.5  108 magnetic beads coated with 15 g of affinity-
purified OT21C, in a 600-l reaction volume (Fig. 1). The
same ratios of reagents and targets were used for subsequent
preparative immunoprecipitations. In the same series of exper-
iments, we were able to show that TRAF3 was coprecipitated
with LMP1 but not the Lyn tyrosine-kinase, although it was
abundant in the C15 raft fraction (Fig. 1). This was a good
indication that we were able to perform selective capture of
LMP1-carrying complexes from a composite mixture of mem-
brane rafts.
FIG. 2. Bidirectional coimmunoprecipitation of galectin 9 and
LMP1 from NPC and LCL cell extracts. (a) Coimmunoprecipitation of
galectin 9 and TRAF3 with the anti-LMP1 antibody OT21C reacting
on NPC and LCL rafts. Raft samples (60 g of protein) were prepared
from the C15 NPC tumor line (NPC) and two EBV-transformed B-cell
lines (EBV1 and NADC15) and submitted to analytical immunopre-
cipitation using 5 g of purified IgG covalently bound to 5  107
magnetic beads. Precipitated proteins were analyzed in two parallel
blots, one stained successively with anti-LMP1 (CS1-4) and anti-galec-
tin 9 and the other stained with anti-TRAF3 antibodies. Input, 5 g of
raft-derived proteins saved prior to the immunoprecipitation step;
mIgG1, control immunoprecipitation performed with mouse non-
specific IgG1; OT21C, LMP1 immunoprecipitation performed with
OT21C (NPC, one-third of the eluted proteins; LCL, one-half of the
eluted proteins). In the case of NADC15, there was a better recovery
for the low-molecular-weight isoform of galectin 9. (b) Coimmunopre-
cipitation of galectin 9 with the anti-LMP1 OT21C and OT22CN
antibodies reacting on whole-tumor extracts. Samples of C15 whole-
tumor extracts (120 g of protein) were submitted to immunoprecipi-
tation using 5 g of purified IgG coated on 5  107 magnetic beads
(without covalent binding). Precipitated proteins were analyzed in
successive Western blots stained with anti-LMP1 (CS1-4) and anti-
galectin 9 antibodies. Because precipitating IgG was not covalently
bound to magnetic beads, it was recovered in the eluate and stained on
the Western membrane with the anti-mouse conjugate, just below the
LMP1 band. Input, crude sample of C15 whole-tumor extract contain-
ing 30 g of protein saved prior to the immunoprecipitation step;
mIgG1, control immunoprecipitation; OT21C, LMP1 immunoprecipi-
tation performed with the OT21C antibody directed to the large C-
terminal intracytoplasmic region (residues 290 to 318) (one-half of the
eluted proteins); OT22CN, LMP1 immunoprecipitation performed
with the OT22CN antibody directed to the short N-terminal intracy-
toplasmic region (residues 1 to 23) (one-half of the eluted proteins).
(c) Lack of coimmunoprecipitation of galectin 9 with an anti-CD40
antibody reacting on whole-tumor extracts. Samples of C15 whole-
tumor extracts (120 g of protein) were submitted to immunoprecipi-
tation using 5 g of purified IgG coated on 5  107 magnetic beads.
Precipitated proteins were analyzed in parallel Western blots stained
with anti-CD40 (MAb 89) and anti-galectin 9 antibodies. Protein gels
prepared for CD40 detection were run in nondenaturing conditions as
required for MAb 89 staining, thereby giving several bands and pre-
cluding molecular weight determination (8). Input, crude sample of
C15 whole-tumor extract containing 40 g of protein saved prior to the
immunoprecipitation step; mIgG1, control immunoprecipitation;
OT21C, LMP1 immunoprecipitation performed with the OT21C an-
tibody (one-half of the eluted proteins); G28-5, CD40 immunoprecipi-
tation performed with the G28-5 antibody (one-half of the eluted
proteins). (d) Coimmunoprecipitation of LMP1 with an anti-galectin 9
antibody reacting on NPC rafts and whole-tumor extracts. C15 rafts
(30 g of protein) were submitted to immunoprecipitation using 2.5 g
of purified rabbit anti-galectin 9 Ig (loaded on 20 l of protein A
beads). Whole-tumor extracts (120 g of protein) were treated with
3.75 g of Ig loaded on 30 l of beads. Precipitated proteins were
analyzed in parallel Western blots stained with anti-galectin 9 (same
rabbit polyclonal) and anti-LMP1 (CS1-4). Input, 10 g of raft-derived
protein or 30 g of whole-tumor extract saved prior to the immuno-
precipitation step; rIg, control immunoprecipitation performed with
nonspecific rabbit Ig; gal9, galectin 9 immunoprecipitation performed
with rabbit polyclonal antibodies directed to the C-terminal carbohy-
drate recognition domain of human galectin 9. This experiment was
performed twice in duplicate. In each case, 25% and 100% of the
eluted proteins were loaded in the gel for galectin 9 and LMP1 detec-
tion, respectively.
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Preparative immunoprecipitation of LMP1 and MS/MS
identification of coimmunoprecipitated proteins. In the next
step, we performed MS/MS analysis of the raft complexes
immunoprecipitated from 180 g of rafts using 4.5  108
magnetic beads coated with 45 g of OT21C antibody. Two
types of negative controls were used: C15 raft complexes sub-
mitted to immunoprecipitation with nonspecific IgG1 and
complexes derived from the LMP1-negative C17 tumor line
treated with OT21C. In order to reduce sample complexity,
precipitated proteins eluted from the beads were submitted to
a short migration (1 cm) on a small PAGE gel which was cut in
nine slices. Proteins extracted from each slice were submitted
to nano-liquid chromatography-electrospray ionization-
quadryde time-of-flight analysis. This whole procedure was
performed twice using either the C17/OT21C or the C15/IgG1
precipitates as controls. Proteins identified at least once in the
C15/OT21C precipitate but not in the controls were retained as
potential LMP1 partners (Table 1). TRAF3 was detected once
in the OT21C precipitate whereas LMP1 itself was never de-
tected, probably because it has only a few trypsin digestion sites
(9 sites for LMP1 in contrast to 75 sites for TRAF3).
Demonstration of LMP1-galectin 9 interactions in NPC and
LCL cells. Subsequent investigations were focused on galectin
9 for two main reasons: (i) this galactosyl binding protein is
known to be very abundant in malignant cells of Hodgkin’s
disease, which is frequently associated with EBV and has in-
tense LMP1 expression (21, 59); (ii) another human galectin,
galectin 4, has been shown to play a role in the stability of lipid
rafts (4, 22). A series of investigations was performed to con-
firm the interactions of LMP1 with galectin 9 using immuno-
precipitation and Western blotting (Fig. 2). Galectin 9 was
coprecipitated from NPC and LCL rafts by OT21C and re-
vealed by using a specific polyclonal antibody. Depending on
the experiment, two to four isoforms of galectin 9 were visu-
alized in the crude raft extract as well as in the precipitate
(Fig. 2a). These isoforms are generated by alternative splicing
of exons 5 and 10, and possibly by posttranslational modifica-
tions (25, 41). Coprecipitation of galectin 9 was observed for
both the EBV1 and NADC15 LCLs which carry the B95-8
and C15 strains of EBV, respectively. Galectin 9 was also
coprecipitated from NPC whole-tumor extracts not only with
the OT21C antibody (directed to the LMP1 C terminus) but
also with OT22CN (directed to the LMP1 N terminus) (Fig.
2b). However, there was a higher relative amount of galectin 9
coprecipitated with OT21C (about 20% instead of 10% for
OT22CN). To further assess the specificity of galectin 9 copre-
cipitation with LMP1, another type of control experiment was
done using an antibody directed to the CD40 receptor, a cel-
lular membrane protein which like LMP1 is constitutively ac-
cumulated in membrane rafts (2, 32). As shown in Fig. 2c, no
galectin 9 was coimmunoprecipitated with CD40. The LMP1-
galectin 9 interaction was also documented by doing coimmu-
noprecipitations of LMP1 with anti-galectin 9 antibodies.
These experiments were performed on NPC rafts and whole-
tumor extracts (Fig. 2d). Although the LMP1 band obtained
from whole-tumor extract was faint, it was consistent in several
experiments. Apparently, a smaller proportion of LMP1 mol-
ecules was coprecipitated with galectin 9 from whole-tumor
extract compared to membrane rafts. One possible explanation
could be that LMP1 and galectin 9 molecules interact more
frequently in membrane rafts than in other cell compartments.
To provide additional evidence of LMP1 interactions with ga-
lectin 9 at the single-cell level, we performed immunofluores-
cence staining of fixed cells and confocal analysis with anti-
LMP1 and galectin 9 antibodies. Partial colocalization of these
two proteins was observed in C15 NPC cells (Fig. 3).
TRAF3 binding to LMP1 is not required for LMP1-galectin
9 interactions. TRAF3 is a major partner protein of LMP1. We
along with others have previously shown that it is recruited by
FIG. 3. Partial colocalization of LMP1 and galectin 9 in NPC cells.
C15 NPC cells were double stained with a mouse anti-LMP1
(OT22CN; red secondary antibody, Alexa 546) (lower left) and a rabbit
anti-Galectin 9 (green secondary antibody, Alexa 488) (upper right).
Overlay (lower right). Scale bar, 1 m. In this typical C15 cell, galectin
9 and LMP1 colocalize in dots where galectin 9 staining is prominent.
FIG. 4. LMP1-TRAF3 binding is not required for LMP1-galectin 9
interactions. (a) Coimmunoprecipitation of LMP1 and galectin 9 from
rafts of HeLa cells stably transfected with the LMP1 gene (HL8 clone)
and transiently transfected with the galectin 9 gene. (b) Coimmunopre-
cipitation of mutated LMP1 (deletion of the PXQXT motif at residues
204 to 208) and galectin 9 from rafts of transiently transfected HeLa
cells. In both cases, raft samples (60 g of protein) were treated with
5 g of purified IgG coated on 0.5 108 magnetic beads (control IgG1
or OT21C). Precipitated proteins were analyzed in parallel Western
blots stained with antibodies directed to LMP1 (CS1-4) and galectin 9
(rabbit polyclonal). WT, wild type.
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LMP1 from the cytosol into membrane rafts (1, 2, 24). To
determine whether TRAF3-LMP1 binding is required for
LMP1 interaction with galectin 9, LMP1-galectin 9 association
was investigated in HeLa cells transfected with the galectin 9
gene and either wild-type B95-8 LMP1 or a mutant LMP1
deleted of the critical TRAF3-binding motif PXQXT (residues
204 to 208) (45). As shown in Fig. 4, galectin 9 was coprecipi-
tated with wild-type or mutant LMP1 with the same efficiency,
providing evidence that TRAF3 is dispensable for galectin
9-LMP1 interaction. In addition, galectin 9 was also readily
coprecipitated with another mutant form of LMP1 deleted not
only of the PXQXT motif but also of the YDD motif (residues
384 to 386) which is required for LMP1-TRADD binding (data
not shown) (37).
FIG. 5. Cell lineage and subcellular distribution of galectin 9. (a) Constitutive expression of galectin 9 in various types of lymphoid and
epithelial cells. EBV1 and NADC15 are EBV-transformed B-cell lines (LCL). Ramos, BL2, and Daudi are Burkitt lymphoma cell lines. BL2-B95
was obtained by EBV conversion of BL2 cells infected with the B95-8 strain. Regarding epithelial cells, all protein extracts were prepared from
xenografted tumors (C15 and C17 are permanently propagated into nude mice; other epithelial cells were specially grown as tumors into nude mice
for the consistency of this analysis). For each cell type, 20 g of whole-cell protein extract was analyzed by Western blotting. (b) Association of
galectin 9 with membrane rafts in both LMP1-positive and -negative NPC cells. C15 and C17 tumor pieces were homogenized in MBS-Triton
buffer, subjected to a raft flotation assay, and analyzed by Western blotting. The flotation assay generates three cell fractions in addition to the raft
fraction: an LSP and an HSP, containing mostly cytoskeletal elements, and fraction F40 recovered in the 40% sucrose layer of the step gradient.
F40 contains most components of the cytosol and nonraft membranes (11). Ten micrograms of protein was loaded per lane. In agreement with
the data presented in panel a, galectin 9 was much more abundant in C15 than in C17 material (corresponding films were exposed 2 and 10 min,
respectively). However, the ratio of galectin 9 concentration in the rafts compared to the initial extract was in the same range for the C15
(LMP1-positive) and the C17 (LMP1-negative) xenografts. (c) Galectin 9 expression in clinical specimens of NPC. NPC tissue sections from nine
patients were stained with a primary anti-galectin 9 and a secondary peroxidase-labeled antibody and finally counterstained with Mayer’s
hematoxylin. Galectin 9 expression by malignant cells was found in all 9 biopsies; it was very intense for seven out of nine cases. Results from two
patients (patients 2 and 3) are presented in this figure. A very strong expression of galectin 9 is visible in tumor cells (T). In contrast, galectin 9
is at a low abundance in the lymphoid stroma (LS) and the adjacent nonmalignant mucosa (PM; parakeratosic mucosa). In the case of patient 3,
the staining of malignant cells is predominant at the plasma membrane.
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Cell and tissue distribution of galectin 9. According to pre-
vious reports, galectin 9 expression is restricted to some nor-
mal tissues and some special types of malignancies (25). To
obtain more information regarding the relationship between
EBV infection and galectin 9 expression, we investigated its
expression in a series of lymphoid and epithelial cells. Very
intense expression was recorded in EBV-positive NPC tumor
lines and EBV-transformed B-cell lines (EBV1 and NAD
C15) (Fig. 5a). In contrast, all Burkitt cell lines were negative
for galectin 9, including one originally infected by EBV
(Daudi) and one converted by in vitro EBV infection (BL2-
B95) (Fig. 5a). Although it was not as high as in C15, galectin
9 expression was very high in the LMP1-negative NPC tumor
lines C17 and C666-1 (Fig. 5a). For both C15 and C17, there
was a preferential association of galectin 9 with membrane
rafts (Fig. 5b). In contrast, no galectin 9 expression or a much
weaker expression was recorded in non-NPC EBV-negative
epithelial cell lines (Fig. 5b). In summary, in vitro investiga-
tions suggested that a very high level of galectin 9 expression
was a specific feature of NPC and LCL cells. To confirm
galectin 9 expression by NPC cells in the patients, a series of
fresh NPC biopsies was analyzed by immunohistochemistry
with our anti-galectin 9 antibody. Intense galectin 9 expression
by malignant cells was found in seven out of nine biopsies. Two
characteristic examples are displayed in Fig. 5c. Two of nine
specimens had weaker galectin 9 expression levels; they were
peculiar, differentiated forms of NPC from French patients.
Staining on infiltrating lymphocytes was much weaker in all
specimens. Adjacent normal mucosa was either completely
negative or weakly stained.
LMP1 and galectin 9 accumulation into NPC cell rafts is not
inhibited by Simvastatin. It has been reported by Katano et al.
that Simvastatin, an HMG (3-hydroxy-3-methylglutaryl)-coen-
zyme A reductase inhibitor and raft-modifying agent, induced
dissociation of LMP1 from lipid rafts and subsequent apopto-
sis of LCL cells in about 5 days (31). Therefore, it was decided
to assess the impact of Simvastatin on the raft distribution of
LMP1 and galectin 9 in NPC cells. First, the range of active
drug concentrations was determined in vitro on cells resulting
from dispersion of the C15 and C17 xenografts using an assay
of cell viability and proliferation. Significant decreases in cell
viability were obtained when cells were treated for 5 days with
concentrations of Simvastatin as low as 2 M. These toxic
effects were similar for the LMP1-positive and -negative NPC
FIG. 6. Cytotoxic effects of Simvastatin on NPC cells. (a) C15 and C17 cells derived from xenografted tumors were short-term cultured for 5
days on a polyHEMA matrix in culture medium supplemented with vehicle (DMSO) only or various concentrations of Simvastatin. Cell viability
was measured at days 1, 3, and 5 using a soluble form of MTT (see Materials and Methods). (b) Low-magnification electron micrographs showing
one example of a C15 cell treated for 5 days with 5 M Simvastatin and several control cells incubated with the vehicle (DMSO) by itself. Among
the morphological changes induced by Simvastatin, note the loss of cellular connections, the transition to round-shaped cells and nuclei, the intense
vacuolization, and the partial chromatin condensation at the periphery of the nucleus. (c) Assessment of PARP cleavage in C15 cells treated by
Simvastatin (Sim) or the vehicle (DMSO) by itself. Thirty micrograms of protein derived from whole-cell extracts was loaded per lane. A positive
control was provided by C15 cells treated with a Fas agonist for 12 h (7C11; 250 ng/ml); this sample contains the cleaved (89 kDa) in addition to
the uncleaved (115 kDa) form of PARP.
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cells derived from the C15 and C17 xenografts, respectively
(Fig. 6a). C15 cells treated with 5 M Simvastatin for 5 days
were examined by electron microscopy. About 50% of treated
cells displayed a morphology suggestive of necrosis (data not
shown). Another subset of about 25% of cells underwent dis-
tinctive morphological changes: a general loss of cell connec-
tions, a transition to round-shaped cells and nuclei, and intense
vacuolization (Fig. 6b). These alterations were reminiscent of
morphological changes previously reported for pancreatic car-
cinoma cells treated with HMG-coenzyme A reductase inhib-
itors (38). In some cells, partial chromatin condensation at the
periphery of the nucleus was suggestive of apoptosis-like pro-
grammed cell death, also called “caspase-independent apopto-
sis” (40) (Fig. 6b). Simvastatin did not stimulate PARP cleav-
age in C15 cells, providing additional evidence that drug
toxicity was not mediated by massive caspase-dependent apo-
ptosis (Fig. 6c). In subsequent experiments, raft distributions
of LMP1, galectin 9, and TRAF3 were investigated in C15 cells
treated with Simvastatin for 5 days. We could see no reduction
in the amount of LMP1, TRAF3, and galectin 9 contained in
C15 rafts using two concentrations of Simvastatin, i.e., 2 M,
which did not induce maximal toxicity (data not shown), and
5 M (Fig. 7a). However, we noted a modest but consistent
increase in the whole-cell concentration of LMP1 and galectin
9 (Fig. 7b).
DISCUSSION
The development of each type of EBV-associated malig-
nancy requires a complex interplay between a specific cellular
context and a specific mode of viral expression. Even in the
restricted field of EBV-associated epithelial malignancies,
there are major differences between EBV-associated gastric
carcinomas and NPC in terms of cell differentiation and viral
gene expression (56). Therefore, it is important to investigate
the status of EBV products in cells that retain, as much as
possible, the characteristics of NPC cells contained in clinical
specimens. Such studies have long been hampered by technical
difficulties in manipulating these cells in vitro. The develop-
ment of proteomic methods has opened new possibilities. By
application of preparative immunoprecipitation and mass
spectrometry analysis on membrane rafts derived from an NPC
xenograft, we have identified galectin 9 as a novel partner of
LMP1. To our knowledge, it is the first example of a membrane
protein that has been shown to specifically interact with LMP1.
All previously described LMP1 partners are cytosolic mole-
cules, for example, the TRAF molecules, TRADD, BRAM1,
and SCF (Skp-cullin-F box) E3 ubiquitin ligase (10, 37, 58). We
have found that galectin 9 is consistently and strongly ex-
pressed in NPC cells; in most cases, it is detected in malignant
cells at a much higher level than in adjacent nonmalignant
mucosa. Galectin 9 was first described in Hodgkin’s disease as
a tumor antigen (59). It has multiple functions including its
role as a membrane urate transporter and eosinophil chemoat-
tractant (25, 41, 42). It has a restricted tissue distribution. In
mice, galectin 9 is strongly expressed by postnatal thymic epi-
thelial cells and plays a role in clonal deletion of immature T
cells (62). Interestingly, both the thymus epithelium and the
nasopharyngeal mucosa derive from the embryonic pharyngeal
endoderm (20). Galectin 9 is also expressed by LCL cells but
not Burkitt lymphoma cells. In other words, all three types of
EBV-transformed cells that have spontaneous LMP1 expres-
sion—Hodgkin cells, NPC, and LCL—also contain a high
amount of galectin 9. However, it is obvious that, in terms of
gene expression, galectin 9 expression is somehow independent
of LMP1. For example, galectin 9 is readily detected in xe-
nografted NPCs lacking LMP1-expression like C17 and
C666-1. On the other hand, it does not show up in Burkitt cells
converted by EBV or transfected with the LMP1 gene. In
summary, galectin 9 expression in NPC seems to reflect a
special mode of nasopharyngeal epithelial cell differentiation
which is exacerbated in the context of cell transformation.
Previous publications have shown that another human galectin,
galectin 4, is accumulated in the rafts of intestinal epithelial
cells, more precisely within a raft core component that is re-
sistant to cholesterol extraction (4, 22). The latest of these
reports provides evidence that galectin 4 plays a role in the
stability of these structures (4). In light of our data, galectin 9
FIG. 7. Impact of Simvastatin on whole-cell concentration and raft
distribution of LMP1, galectin 9, and TRAF3 in NPC cells. C15 cells
derived from xenografted tumors were short-term cultured for 5 days
on a polyHEMA matrix in the presence of 5 M Simvastatin or DMSO
alone and then subjected to protein extraction and a raft flotation
assay. (a) Raft flotation assay of C15 cells treated by Simvastatin (Sim)
or the vehicle (DMSO) by itself. The flotation assay generates three
cell fractions in addition to the raft fraction: LSP and HSP containing
mostly cytoskeletal elements and a fraction called F40 recovered in the
40% sucrose layer of the step gradient. F40 contains most components
of the cytosol and nonraft membranes (11). Ten micrograms of pro-
teins was loaded per lane. Parallel blots were done for detection of
LMP1, TRAF3, and galectin 9. For all three proteins, the ratio of
protein concentration in the rafts compared to the initial extract is not
significantly different between Simvastatin-treated and control cells.
(b) Comparison of whole-cell concentrations of LMP1, galectin 9, and
TRAF3 in C15 cells treated for 5 days by Simvastatin (Sim) or the
vehicle (DMSO) by itself (30 g of protein per lane). An approximate
twofold increase is observed in the whole-cell concentrations of LMP1
and galectin 9 in C15 cells treated by Simvastatin compared to the
control.
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appears as one novel example of a galectin associated with
membrane rafts.
The detection of large amounts of galectin 9 in NPC cells
might also benefit our understanding of host-tumor interac-
tions. NPCs are characterized by the presence of viral antigens
in a highly inflammatory context, and the mechanisms of local
immune tolerance are still poorly understood (3, 61). There-
fore, it is noteworthy that galectin 9, like some other galectins,
can act as a negative regulator of T-cell activation (30, 53).
Because of its inhibitory effects on T cells, galectin 9 might
possibly contribute to viral immune escape in NPC tumors.
This hypothesis is supported by some of our recent experi-
ments, which indicate that both LMP1 and galectin 9 can be
released in the extracellular medium by NPC cells.
We have previously reported that LMP1 recruits its main
adaptor TRAF3 in membrane rafts to the exclusion of TRAF2,
TRAF1, or TRADD (1, 2). In contrast, galectin 9 is not re-
cruited in membrane rafts by LMP1. It appears to be a resident
raft protein even in the absence of LMP1, for example, in the
C17 xenograft. In addition, it seems to be much more abundant
than LMP1 in membrane rafts. According to preliminary ex-
periments, the amount of LMP1 and galectin 9 molecules for
10 g of rafts is about 200 and 1,200 fmol, respectively. This
might explain the fact that it was difficult to precipitate more
than 20% of the galectin 9 contained in the cellular extract
even when it was possible to precipitate almost 100% of LMP1
(Fig. 2b). Using mutant forms of LMP1 expressed in HeLa
cells, we have shown that its critical TRAF3- and TRADD-bind-
ing motifs are not required for its interaction with galectin 9. So
far, we do not know whether LMP1 directly binds to galectin 9
or whether this interaction is mediated by other molecules,
either lipids or proteins. Previous reports have shown that the
short intracytoplasmic domain and a conserved motif of the
first transmembrane segment are critical for LMP1 association
with membrane rafts (12, 51, 65). Our ongoing experiments are
intended to determine whether the same segments of LMP1
are required for its interaction with galectin 9.
Our data regarding LMP1-galectin 9 interactions provided a
good molecular basis to investigate the effects of Simvastatin
on the behavior of LMP1-carrying rafts in NPC cells. Treat-
ment of C15 cells with Simvastatin was expected to induce the
dissociation of LMP1 from membrane rafts, as previously re-
ported for LCLs by Katano et al. (31). It was not the case: the
raft distribution of LMP1 and TRAF3 as well as galectin 9 was
apparently not affected by this drug, despite its strong cytotoxic
effect. At the same time, the whole-cell concentrations of
LMP1 and galectin 9 were increased under Simvastatin. Cur-
rently, we have no explanation for this modification. In any
case, the cytotoxic effect of Simvastin against NPC cells was
almost the same for C15 (LMP1-positive) and C17 (LMP1-
negative) cells, providing additional evidence that LMP1 is not
a critical lethal target for Simvastatin in this cell type. Inter-
estingly, the cytotoxic effect of Simvastatin against NPC cells
was obtained at low concentrations: a concentration of only
1 M for 2 days was sufficient to induce significant growth
inhibitory effects in contrast to a concentration of more than
10 M required to achieve a significant effect on prostate car-
cinoma cells (67). Thus, our data suggest that Simvastatin
might be beneficial in some circumstances for NPC patients.
This is especially interesting since this drug has been widely
used in medical practice for several years, allowing long-term
monitoring of its undesirable effects.
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